We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Read MoreHide Full Article
Immuneering Corporation (IMRX - Free Report) announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.
The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.
IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.
Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.
Image Source: Zacks Investment Research
Recent Developments Related to IMRX's IMM-1-104
Last month, the company announced positive early response data from the first five patients of an ongoing early to mid-stage study evaluating IMM-1-104 combined with chemotherapy (modified gemcitabine/nab-paclitaxel) in first-line pancreatic cancer.
IMM-1-104, an investigational RAS medication, is being evaluated in the phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.
A phase IIa study is evaluating the 320mg dose of IMM-1-104 as a monotherapy and in combination with two different chemotherapy regimens to treat pancreatic cancer. The phase IIa portion is also evaluating IMM-1-104 as monotherapy for non-small cell lung cancer and melanoma in different treatment arms.
The combination regimen of IMM-1-104 and modified gemcitabine/nab-paclitaxel was also overall well tolerated by the pancreatic cancer patients in the phase IIa portion of the study with a consistent safety profile for both therapeutics.
Initial data from at least one additional arm of the phase IIa portion of the early to mid-stage study is expected by the end of 2024.
Besides IMM-1-104, Immuneering has another pipeline candidate, IMM-6-415, which is being evaluated in a separate phase I/IIa study in patients with advanced solid tumors harboring RAS or RAF mutations.
In the absence of an approved product, pipeline development remains in key focus for the company.
IMRX's Zack Rank & Stocks to Consider
Immuneering currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.69 to $4.81. Earnings per share estimates for 2025 have improved from $5.37 to $5.86. Year to date, shares of ANIP have increased 6.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Voyager Therapeutics’ 2024 loss per share have narrowed from $1.47 to $1.44. Loss per share estimates for 2025 have narrowed from $1.95 to $1.94. Year to date, shares of VYGR have declined 18.8%.
VYGR’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 104.33%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 26 cents. Year to date, shares of ALNY have rallied 50.2%.
ALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Immuneering Corporation (IMRX - Free Report) announced that the FDA has granted orphan drug designation to its lead product candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares of the company were up 15.5% on Oct. 15 following the announcement of the news.
The FDA grants Orphan Drug Designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The Orphan Drug Designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies as well as exemptions from certain FDA application fees.
IMM-1-104 was earlier granted the FDA’s Fast Track designation in the United States for the treatment of first- and second-line pancreatic cancer.
Year to date, shares of Immuneering have plunged 68.6% compared with the industry’s decrease of 1.8%.
Image Source: Zacks Investment Research
Recent Developments Related to IMRX's IMM-1-104
Last month, the company announced positive early response data from the first five patients of an ongoing early to mid-stage study evaluating IMM-1-104 combined with chemotherapy (modified gemcitabine/nab-paclitaxel) in first-line pancreatic cancer.
IMM-1-104, an investigational RAS medication, is being evaluated in the phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.
A phase IIa study is evaluating the 320mg dose of IMM-1-104 as a monotherapy and in combination with two different chemotherapy regimens to treat pancreatic cancer. The phase IIa portion is also evaluating IMM-1-104 as monotherapy for non-small cell lung cancer and melanoma in different treatment arms.
The combination regimen of IMM-1-104 and modified gemcitabine/nab-paclitaxel was also overall well tolerated by the pancreatic cancer patients in the phase IIa portion of the study with a consistent safety profile for both therapeutics.
Initial data from at least one additional arm of the phase IIa portion of the early to mid-stage study is expected by the end of 2024.
Besides IMM-1-104, Immuneering has another pipeline candidate, IMM-6-415, which is being evaluated in a separate phase I/IIa study in patients with advanced solid tumors harboring RAS or RAF mutations.
In the absence of an approved product, pipeline development remains in key focus for the company.
IMRX's Zack Rank & Stocks to Consider
Immuneering currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Voyager Therapeutics, Inc. (VYGR - Free Report) and Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.69 to $4.81. Earnings per share estimates for 2025 have improved from $5.37 to $5.86. Year to date, shares of ANIP have increased 6.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Voyager Therapeutics’ 2024 loss per share have narrowed from $1.47 to $1.44. Loss per share estimates for 2025 have narrowed from $1.95 to $1.94. Year to date, shares of VYGR have declined 18.8%.
VYGR’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 104.33%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 26 cents. Year to date, shares of ALNY have rallied 50.2%.
ALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.